Article

FCS Advancing Therapies for Patients Through Clinical Research in Community Oncology Practices

Florida Cancer Specialists & Research Institute provides the newest cancer therapies, some not yet available elsewhere, through convenient access to clinical trials.

The survival rate for Americans diagnosed with several of the most common cancers has increased dramatically in the past nearly 3 decades, thanks in large part to scientific discoveries and treatment advances. Florida Cancer Specialists & Research Institute (FCS) physicians and patients are part of these leading-edge cancer innovations, providing the newest cancer therapies, some not yet available elsewhere, through convenient access to clinical trials.

This is possible through FCS' long-standing partnership with Sarah Cannon—a trusted expert in the field of oncology research having conducted more than 500 first-in-human trials and been a clinical trial leader in the majority of approved cancer therapies over the last decade.

Since the inception of our research program, 10,000 patients have participated in innovative studies.

Learn more.

Related Videos
Douglas Flora, MD, FACCC
rachel rohaidy
Douglas Flora, MD, FACCC
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Rachel Rohaidy, MD
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Rebecca Haberman
Frederick L. Locke, MD
Screenshot of an interview with Shaun McKenzie, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo